Factory Supply Bortezomib powder CAS: 179324-69-7

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 10.0000

1 Gram

FOB Price: USD 10.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other

Keywords

Bortezomib 179324-69-7 Bortezomib powder

Quick Details

Appearance:white powder
Application:anti-cancer
PackAge:10G/bag
ProductionCapacity:10|Metric Ton|Year
Storage:Room temperature
Transportation:Regular transportation

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Our Advantange of Bortezomib powder CAS: 179324-69-7:

Best Quality and Competive price

Details:

the information of Bortezomib powder CAS: 179324-69-7:

Product name	Bortezomib
CAS No.	179324-69-7
Molecular Formula	C19H25BN4O4
Molecular Weight	384.24
Quality Standard	99% up, Medicine Grade
Appearance	White powder

The COA of Bortezomib powder CAS: 179324-69-7

The use of Bortezomib powder CAS: 179324-69-7:

Bortezomib is a new targeted drug for myeloma. The discovery of this drug has attracted wide attention in the medical field, and its mechanism of action won the Nobel Prize in Chemistry in 2004. In 2006, bortezomib was awarded the Highest honor in the pharmaceutical industry -- The International Galen Prize (PrixGalien).Before bortezomib, multiple myeloma was a nightmare for patients with the disease.

Bortezomib, as a breakthrough drug for myeloma, has the following advantages:

1.It only takes about 1 month to take effect.

2. The curative effect is remarkable, the remission rate can reach more than 80Chemicalbook%, and the complete remission rate can reach 30%~40%.Bortezomib in combination with lenalidomide and dexamethasone (BRD) extended median survival by 11 months compared with lenalidomide in combination with dexamethasone (RD), with median survival of 75 months in the BRD group.

3. High safety, can be applied to patients with renal insufficiency or even renal failure, the efficacy is equivalent to that of patients with normal renal function, and can reverse renal function;

4. Bortezomib based induction therapy can significantly increase the number and speed of stem cell collection.

View All

Visit Store